The IXICO Platform is an AI-enabled technology platform purpose built for neuroimaging data management and analysis to enable better disease research, diagnosis, understanding, treatment and management.
The Platform’s suite of tools and services operates across the entire clinical trial workflow to deliver an advanced set of disease specific clinical endpoints, from relevant PET / SPECT tracers (e.g. amyloid, tau, FDG, TSPO, DAT) and MRI sequences (e.g. structural, DTI, fMRI, MRS, ASL, QSM and neuromelanin), while minimising variability and maintaining reproducibility.
| ADVANCED |
Highly advanced neuroimaging technology to improve the assessment of drug safety, patient eligibility and drug efficacy, enabling very complex neurological analysis at scale |
| END-TO-END | a total solution integrating automated and manual neuroimaging data processes from scientific definition to site set up, data upload, reading, analysis, quality control and secure transfer. |
| ACCURATE | delivering critical clinical endpoints while reducing variability by automating traceability and consistent reproducibility into every dataset. |
| COMPATIBLE | reduces the data upload, management and analysis burden for sponsors and readers through seamless integration with existing workflows without the need for additional software or tools. |
| SCALEABLE | capable of supporting any number of clinical trials and handling very large volumes of imaging data. |
| REGULATORY | expert in quality management processes compatible with national and international regulatory frameworks. |
| FLEXIBLE | an adaptable platform supporting individual disease area needs with the required specialism and indication-specific analysis tools. |
The latest generation of the Platform positions IXICO’s technology beyond its traditional iCRO remit and opens opportunities to expand into diagnostics, mechanistic disease understanding, patient selection/stratification, pre-clinical drug candidate validation and clinical decision support.